ArticleJournal for immunotherapy of cancer2019
miR-34a as hub of T cell regulation networks.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Targeting VAMP5 suppresses PLK1-driven growth of gliomas with high NDRG4 expression.Journal of neuro-oncology · 2026Article
- Tumor-derived small extracellular vesicles loaded with functionally active miR-34a mimic can modify the anti-tumor response in 4T1 breast cancer animal model.Cancer cell international · 2025Article
- Exosomal microRNAs in common mental disorders: Mechanisms, biomarker potential and therapeutic implications.World journal of psychiatry · 2025Review
- Interplay between innate-like T-cells and microRNAs in cancer immunity.Discover oncology · 2025Review
- A polycistronic locus encodes both a tumor-suppressive microRNA and a long non-coding RNA regulating testis morphology in Drosophila.bioRxiv : the preprint server for biology · 2025Article
- miR-335-5p Inhibits EMT and PI3K/AKT Pathways via MARCH8.Indian journal of clinical biochemistry : IJCB · 2025Article
- Interpretable machine learning-driven biomarker identification and validation for Alzheimer's disease.Scientific reports · 2024Article
- miR-34a promotes the immunosuppressive function of multiple myeloma-associated macrophages by dampening the TLR-9 signaling.Cancer medicine · 2024Article
- Experimental capture of miRNA targetomes: disease-specific 3'UTR library-based miRNA targetomics for Parkinson's disease.Experimental & molecular medicine · 2024Article
- The miRNA-target interactions: An underestimated intricacy.Nucleic acids research · 2024Review
- Exploring the nexus between MYH9 and tumors: novel insights and new therapeutic opportunities.Frontiers in cell and developmental biology · 2024Review
- MicroRNAs as Key Regulators in RA and SLE: Insights into Biological Functions.Current pharmaceutical design · 2024Review
- A Novel Bioswitchable miRNA Mimic Delivery System: Therapeutic Strategies Upgraded from Tetrahedral Framework Nucleic Acid System for Fibrotic Disease Treatment and Pyroptosis Pathway Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA/NKG2D pathway.Biomarker research · 2023Review
- AAV-mediated delivery of osteoblast/osteoclast-regulating miRNAs for osteoporosis therapy.Molecular therapy. Nucleic acids · 2022Article
- Article
- Anti-Inflammatory microRNAs for Treating Inflammatory Skin Diseases.Biomolecules · 2022Review
- Systems biology models to identify the influence of SARS-CoV-2 infections to the progression of human autoimmune diseases.Informatics in medicine unlocked · 2022Article
- Association between miR-126, miR-21, inflammatory factors and T lymphocyte apoptosis in septic rats.Molecular and clinical oncology · 2021Article
- Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.BMC anesthesiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimental confirmation. Here, miR-34a, a well-known tumor suppressor, is analyzed for targeting genes involved in immune system processes of leucocytes.
methodsUsing an in-silico approach, we combined miRNA target prediction with GeneTrail2, a web tool for Multi-omics enrichment analysis, to identify miR-34a target genes, which are involved in the immune system process subcategory of Gene Ontology.
resultsOut of the 193 predicted target genes in this subcategory we experimentally tested 22 target genes and confirmed binding of miR-34a to 14 target genes including VAMP2, IKBKE, MYH9, MARCH8, KLRK1, CD11A, TRAFD1, CCR1, PYDC1, PRF1, PIK3R2, PIK3CD, AP1B1, and ADAM10 by dual luciferase assays. By transfecting Jurkat, primary CD4
conclusionsBy simultaneous targeting of 14 mRNAs miR-34a acts as major hub of T cell regulatory networks suggesting to utilize miR-34a as target of intervention towards a modulation of the immune responsiveness of T-cells in a broad tumor context.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.